Kornimate/medical-research-clean huggingface dataset:
role of the inflammatory receptors in the pathogenesis of atherosclerosis

Conditions: Coronary Artery Disease

Summary: the primary objective of this study is to assess whether inflammatory receptors play a role in the pathogenesis of atherosclerosis.

atherosclerosis is a chronic inflammatory disease characterized by lipid deposition and macrophages/foam cell accumulation beneath the arterial intima. immune competent cells are abundant in atherosclerotic lesions, where they produce mainly proinflammatory cytokines. macrophages play a central role in each stage of the pathogenesis of atherosclerosis. at the beginning, the so-called foam cells contribute to the formation of early lesions; in mature plaques, macrophages constitute 50% of the cells in the lesion; finally, they are involved in the mechanisms leading to plaque rupture. the primary objective of this study is to assess whether the inflammatory receptors play a role in the pathogenesis of atherosclerosis.

Eligibility criteria:
study population 1 patients with st-elevation myocardial infarction (stemi) with angiographic evidence of massive thrombosis in the culprit artery undergoing primary percutaneous coronary intervention (pci) criteria inclusion criteria: * st-elevation myocardial infarction * angiographic evidence of massive thrombosis in the culprit artery * indication to primary percutaneous coronary intervention (pci) * able to understand and willing to sign the informed cf exclusion criteria: • women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before ct study population 2 patients with coronary artery disease in stable conditions scheduled to undergo elective percutaneous coronary intervention and patients with criteria inclusion criteria: * a de novo native coronary artery lesions (reference vessel diameter:2.5-3.75 mm) * class i indication to elective percutaneous coronary intervention * stable conditions and no recent acute coronary syndromes * normal baseline values of markers of myocardial damage (creatine kinase, creatine kinase-mb, myoglobin, and troponin i) * able to understand and willing to sign the informed cf exclusion criteria: • women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before ct

Keywords: coronary artery disease percutaneous coronary intervention inflammatory receptors
impact of socioeconomic inequalities in transition between health, multimorbidity and death amongst older people

Conditions: Multimorbidity

Summary: life expectancy at age 65 in the most deprived fifth of the english population was about 4 years shorter than of the most affluent fifth in 2010. the inverse gradient between mortality and social position is well established. but how disease patterns and multimorbidity (having two or more long term conditions at the same time) impact on differential mortality rates is inconclusive: is it because disadvantaged groups acquire more or more lethal combinations of, diseases over their life course; or, simply, become ill at ages younger than more affluent groups?

the association between social inequality and cause-specific mortality and single disease morbidity has been studied extensively. however, it remains unclear whether having two or more chronic diseases concurrently (or 'multimorbidity') plays a role in contributing to the inequalities gap in survival. this is particularly relevant given an ageing population and the trend of a widening in the life expectancy gap across several european countries. multimorbidity incidence increases rapidly with age. estimates of the prevalence of multimorbidity in older people range from 55% to 98%, mainly due to the selection of diseases included, population coverage (hospital, community) and data source (self-reported surveys or clinical records). however, across all studies there is a clear and consistent pattern of higher prevalence rates at older ages, with multimorbidity. many aspects of the patient health trajectory remain under-explored. patient case-mixes are likely to vary across socioeconomic groups, alongside a host of prognostic factors, including the clustering of multiple risk factors, age of onset, and disease presentation, progression and management in the presence of multiple health conditions.

Eligibility criteria:
inclusion criteria: * registered with a participating practice that has agreed to data linkage * registered with an 'up to standard' participating general practice for at least 1 year * aged 45 and over on jan 1st 2001 or who turn 45 between 1st jan 2001 and 25th march 2010, irrespective of initial health status. exclusion criteria: * patients with a record unlinked to deprivation due to missing or incomplete postcode of residence.

Keywords: multimorbidity health inequalities ageing mortality
efficacy and safety study of fosmetpantotenate (re-024) in pkan participants

Conditions: Pantothenate Kinase-Associated Neurodegeneration

Summary: this study investigated whether fosmetpantotenate (re-024), a phosphopantothenate replacement therapy, was safe and effective in treating participants with pkan.


Eligibility criteria:
inclusion criteria: 1. the participant had a diagnosis of pkan as indicated by confirmed mutations in the pantothenate kinase 2 gene. 2. the participant was male or female aged 6 to 65 years, inclusive. 3. the participant had a score of ≥ 6 on the pkan-specific activities of daily living measure. exclusion criteria: 1. the participant had required regular or intermittent invasive ventilatory support to maintain vital signs within 24 weeks prior to randomization. 2. the participant had a deep brain stimulation device implanted within 6 months prior to screening. 3. the participant had taken deferiprone within 30 days prior to screening. 4. the participant was unable to maintain stable doses of allowed concomitant medications for the first 24 weeks of the study.

Keywords: pkan
clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome

Conditions: Neonatal Abstinence Syndrome

Summary: to test the hypothesis that the combination of the tincture of opium (dto) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (dto) alone.


Eligibility criteria:
* neonates born at gestational age of 35 weeks or greater * neonates aged 0 to 14 days * prenatally exposed to opioids * severe nas defined as 2 consecutive modified finnegan scores (mfs) \> or = 9 exclusion criteria: * \< 35 weeks gestational age * intrauterine growth retardation defined as \<5%tile of gestational age * postnatal treatment with barbiturates or benzodiazepines, * major congenital anomalies * major concomitant medical illness requiring oxygen therapy, intravenous fluids or medications. * breastfed infants

Keywords: infants opioid withdrawal abstinence syndrome methadone heroin
precision cell immunotherapy combined with chemotherapy in advanced lung cancer

Conditions: Precision Cell Immunotherapy; Chemotherapy; Advanced Lung Cancer

Summary: to evaluate the safety and effectiveness of cell therapy using precision cell immunotherapy to treat advanced lung cancer. eligibility: individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with advanced lung cancer.

a total of 40 patients may be enrolled over a period of 1-2 years.

Eligibility criteria:
inclusion criteria: 1. age 18\~65 years old, male or female; 2. life expectancy≥6 months; 3. ecog score: 0-3; 4. advanced malignancies (lung cancer) were diagnosed by pathological or clinical physicians; 5. enough venous channel, no other contraindications to the separation and collection of white blood cells; 6. laboratory examination: white blood cell≥3 x 10\*9/l, blood platelet count≥60 x10\*/l,hemoglobin≥85g/l; lymphocyte count≥15%, total bilirubin≤100 mol/l; alt and ast less than five times of the normal level; serum creatinine less than 1.5 times of the normal level； 7. signed informed consent； 8. women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion. exclusion criteria: 1. expected overall survival \< 6 months; 2. patients with uncontrolled hypertension (\>160/95mmhg), unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (\> class ii, nyha), or myocardial infarction within 6 months. 3. other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc; 4. other drugs, or other biological treatment,chemotherapy or radiotherapy are performed within a month. 5. unable or unwilling to provide informed consent, or fail to comply with the test requirements.

Keywords: precision cell immunotherapy chemotherapy advanced lung cancer
prediction of bk virus reactivation in kidney transplant recipient

Conditions: Kidney Transplant Infection; BK Virus Infection; BK Virus Nephropathy

Summary: there has been no effective predicting tool to accurately predict bkv reactivation after kidney transplantation. the aim is to elucidate the use of flow cytometric analysis for both intracellular cytokines and surface activation markers for bkv-specific t cell response in kidney transplant recipients.


Eligibility criteria:
inclusion criteria: 1. new kidney transplantation cases (either living donor or deceased donor transplantation) 2. age ≥ 18 years old 3. agree to give a permission to blood sampling post-transplantation, and at the time of bk viremia. exclusion criteria: 1. pregnant 2. primary non-function of kidney allograft (i.e. kidney allograft never function).
a 6-week study to determine the safety and effect of an investigational drug given with canagliflozin in adults with type 2 diabetes mellitus taking metformin

Conditions: Type 2 Diabetes Mellitus

Summary: a phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (bid), for 6 weeks, with canagliflozin, in adult subjects with type 2 diabetes mellitus (t2dm).


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus and treated with metformin at a dose greater than or equal to 1000 mg for at least 3 months and are willing to switch to canagliflozin from metformin for the duration of the study * hemoglobin a1c of 7-10% at screening. * body mass index of at least 25 kg/m2. exclusion criteria: * compliant with study drug administration during the run-in period and throughout the trial. * patients with fasting triglycerides greater than 500 mg/dl at screening. * history of certain diabetic complications or cardiac problems.
modification of the local abnormal ventricular activity only

Conditions: Ventricular Tachycardia

Summary: local abnormal ventricular activity (lava) is composed of high-frequency, mainly low voltage signals that represent near-field signals from slow-conducting tissue and thus potential vt isthmuses. the identification of lava potentials and their modification have usually been a complimentary component of the substrate-based modification of scar related ventricular arrhtyhmias. with better identification through technical solutions and improved algorithms, lava modification may be feasible for treatment in therapy refractory vt.

as of 2019 we started lava modification only in a subset of patients with therapy refractory ventricular tachycardia. the cohort icludes 55% patient with ischemic cardiomyopathy and 45% with dilated cardiomyopathy. 80% are icd recipients. these patients were now retrospectively analysed in depth. the endpoint is time to relapse of ventricular tachycardia or icd shock or death due to malignant arrhythmia. we evaluated all patients we treated accordingly from march 2019 through october 2020. no patient was excluded.

Eligibility criteria:
inclusion criteria: therapy refractory ventricular arrhythmia exclusion criteria: none

Keywords: local abnormal ventricular activity substrate modification electrophysiology lava decremental
disseminating a model intervention to promote improved attention-deficit hyperactivity disorder (adhd) care in the community

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the american academy of pediatrics (aap) has established a set of consensus guidelines for pediatricians to follow. these guidelines can be challenging to implement in typical community-based practices. cincinnati children's hospital medical center (cchmc) has developed a program called the adhd collaborative to promote the adoption of these guidelines among community pediatricians. the program focuses on modifying the office system using academic detailing and quality improvement (qi) methodology to accommodate prescribed practice changes. the adhd collaborative has been very successful at recruiting practices in the greater cincinnati area, changing practice behaviors, and sustaining these practice behaviors over time at minimal cost to the project and to the office practice. now that sustainability and effectiveness have been established, the next step is to modify the adhd collaborative model to make it amenable to widespread dissemination. the primary goal of the proposed study is to modify the adhd collaborative intervention to make it transportable and then evaluate this version in terms of effectiveness, consumer satisfaction, and costs.. a transportable intervention is described that utilizes telehealth videoconferencing, a web portal, and long-distance data collection. initially, three pediatric practices will be recruited to test and refine the distal intervention delivery methodology. then, eight new pediatric practices will be randomly assigned to receive the distal intervention or to a control group (treatment as usual). information about pediatric practice behavior will be collected at baseline, 6-months, and 1-year post-baseline. the study design will allow for a preliminary assessment of the feasibility and effectiveness of the distal intervention in terms of rates of evidence-based practice behaviors to patients, change in pediatrician attitudes, consumer satisfaction, and costs.


Eligibility criteria:
inclusion criteria: * pediatric practice with at least 2 physicians exclusion criteria: * no electronic billing system

Keywords: adhd
wound infiltration as part of an opioid free pain management pathway following cesarean delivery

Conditions: Pain, Postoperative; Anesthesia, Local; Opioid Use

Summary: this study will investigate the effect of three types of wound infiltration on post cesarean opioid analgesia consumption when used in conjunction with an opioid free postoperative analgesia pathway.

the subjects that meet the inclusion criteria of the study will be randomized preoperatively into three arms following a 1:1:1 ratio. during the intraoperative course one of three combinations of wound infiltration will be administered to subjects prior to the closure of the surgical incision. subjects in group i will receive a placebo of normal saline. subjects in group ii will receive bupivacaine alone. subjects in group iii will receive both bupivacaine and dexmedetomidine.

Eligibility criteria:
inclusion criteria: * all scheduled cesarean deliveries with intrathecal or epidural anesthesia exclusion criteria: * emergency cesarean deliveries * multifetal gestation * subjects \<18 years old * subjects belonging to a vulnerable population (including subjects with a known opioid addiction, subjects with a history of mental illness and prisoners) * cesarean delivery with general anesthesia * known allergy or hypersensitivity to any of the study medications * subjects that can't comprehend the visual analog scale for quantitative pain assessment

Keywords: wound infiltration post cesarean pain management bupivacaine dexmedetomidine postoperative pain
practicing restorative yoga or stretching for the metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the purpose of this study is to determine whether restorative yoga versus stretching exercises will reduce risk factors for metabolic syndrome in adults with metabolic syndrome.

metabolic abnormalities, including visceral adiposity, insulin resistance, hyperglycemia, hypertension and dyslipidemia, occur together and are associated with excessive caloric intake and inadequate physical activity. persons with the metabolic syndrome are at high risk of developing type 2 diabetes and cardiovascular disease. lifestyle and behavioral interventions reduce these risks, but many individuals with increased metabolic risk find it difficult to achieve and maintain weight loss and increased physical activity. we are conducting a rigorous randomized controlled trial at two clinical sites to determine if restorative yoga compared to stretching exercises improves the metabolic syndrome among overweight and underactive individuals who meet criteria for the metabolic syndrome.

Eligibility criteria:
inclusion criteria: * anyone between the ages of 21 and 65 who may meet the criteria for the metabolic syndrome can sign-up for the screening process. a more thorough screening process will be conducted to determine whether or not you are eligible to enroll in the study * underactive * overweight exclusion criteria: * pregnancy or breast feeding * chronic illnesses: cancer, kidney disease, cirrhosis of the liver, rheumatologic diseases, or chronic infections * not ambulatory or neurological condition causing impaired mobility * weight over 400 pounds * history of or plans for bariatric surgery * inability to speak and read english

Keywords: metabolic syndrome restorative yoga stretching visceral adiposity randomized controlled trial
registry of subject treated with clarifix

Conditions: Chronic Rhinitis

Summary: a multi-center, prospective, non-randomized, observational registry to asses the results of the clarifix(tm) device when used to ablate unwanted tissue in the nose of subjects with chronic rhinitis.


Eligibility criteria:
inclusion criteria: * participant is scheduled to receive treatment with the clarifix device in accordance with the clarifix instructions for use. * participant is able to provide consent and willing to adhere to the study visit schedule. exclusion criteria: * participant is scheduled to have additional treatment and/or procedures completed at the same time of treatment with the clarifix device. * participant is scheduled to have additional nasal or sinus treatments and/or procedures completed within 3 months of treatment with the clarifix device.
usefulness of dexmedetomidine on post-operative pain management in patients with interstitial cystitis

Conditions: Interstitial Cystitis

Summary: the purpose of this study is to assess the effects of dexmedetomidine while patients undergo treatment for interstitial cystitis (ic). the investigators goal is to demonstrate in patients with ic undergoing bladder hydrodistension that the use of dexmedetomidine as a supplemental anesthetic agent will result in better postoperative pain management.

inclusion criteria: patients with a clinical diagnosis of ic scheduled for cystoscopy and hydrodistension for both diagnostic and therapeutic indications. data collected will include: i. postoperative outcomes i. pain reported (visual analogue scale) ii. post-operative opiate use iii. time in pacu iv. time until discharge v. adverse events (i.e. nausea/vomiting, nursing intervention) ii. intermediate-term outcomes (4-6 weeks) i. interstitial cystitis symptom \& problem index ii. revised mcgill pain score

Eligibility criteria:
inclusion criteria: * patients with a clinical diagnosis of ic scheduled for cystoscopy and hydrodistension for both diagnostic and therapeutic indications. * 2. gender of patients: male \& female,age of patients: 18 and older exclusion criteria: * conduction disturbance (second degree av block or greater), or previous reaction to medications used in this study. patients receiving spinal anesthesia will not be included.

Keywords: post-operative pain management pain management painful bladder syndrome frequency and urgency dexmedetomidine hydrodistension
supervised treadmill exercise and ranolazine for intermittent claudication of lower extremities

Conditions: Peripheral Arterial Disease

Summary: the goal of this study is to evaluate whether supervised treadmill exercise combined with ranolazine 1000 mg twice daily provides an incremental benefit in absolute walking distance over supervised exercise alone in patients with stable claudication. investigators also seek to determine if the administration of ranolazine provides a sustained benefit after the completion of a supervised exercise regimen. lastly, investigators wish to determine whether both exercise and ranolazine improves peak oxygen consumption and anaerobic threshold in patients with stable claudication.

the treatment groups are: a. group a will be randomized to a 12 week supervised exercise program and ranolazine, (ranexa) 1000 mg orally, twice daily, by mouth. b. group b will be randomized to a 12 week supervised exercise program and placebo. after the 12 week supervised exercise program, all participants will undergo a second randomization to ranolazine or placebo for an additional 12 weeks, during which independent walking will be encouraged. both groups will participate in a two week lead-in period after each randomization of the trial, allowing for the stabilization of their medications and dosing of ranolazine. medications such as cilostazol, calcium channel blockers and nitrates will be discontinued during the lead-in period, unless their use is for management for high blood pressure. anti-platelet (blood thinner) medications will be continued throughout the trial.

Eligibility criteria:
inclusion criteria: * males or females greater than 40 years of age. * documented peripheral arterial disease * stable lower extremity intermittent claudication (rutherford class 1-3) for 3 months. exclusion criteria: * critical limb ischemia (rutherford class 4-6). * percutaneous or surgical lower extremity revascularization within last 12 months. * myocardial infarction within the last 6 months. * cardiac surgery within the last 6 months. * unstable angina * stable chronic angina * new york heart association class ii-iv heart failure * left ventricular ejection fraction less than or equal to 35% * venous thromboembolism within the last 6 months. * uncontrolled high blood pressure, defined as systolic blood pressure greater than or equal to 180 mmhg or diastolic blood pressure greater than or equal to 110 mmhg. * allergy to ranolazine. * corrected qt interval (qtc) greater than or equal to 440 ms in males or 460 ms in females. * pregnant or nursing females. * chronic dialysis therapy. * significant liver impairment (defined as transaminases greater than or equal to 3 times the upper limit of normal) within the last 6 months. * concomitant use of cytochrome p450-3a (cyp3a) inhibitors * concomitant use of cyp3a inducers * qtc prolonging agents * orthopedic or neurologic disorders that prevent treadmill walking. * current participation in a structured exercise program.

Keywords: lower leg claudication poor circulation of the leg muscles cramping or discomfort in the lower legs lower leg pain pad (peripheral arterial disease)